SEC Form 4 · accession 0001179110-15-016059
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nesli Basgoz
Director
Period of report
Dec 7, 2015
Accepted (ET)
Dec 9, 2015 · 4:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary shares, par value $0.0001 | Dec 7, 2015 | M | 2,300 | $82.53 | A | 6,362 | D | |
| Ordinary Shares, par value $0.0001F1,F2 | Dec 7, 2015 | S | 2,300 | $312.96 | D | 4,062 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $82.53 | Dec 7, 2015 | M | 2,300 | D | — | May 18, 2016 | Ordinary Shares | 2,300 | 459 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $312.93 to $312.986, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
- F3This option became vested and exercisable in four equal installments commencing on May 18, 2006.